comparison of dabigatran vs. warfarin in acute vnous thromboemboly: systematic review

abstract:acute venous thromboembolism (vte) is a common disease associated with the significant morbidity and mortality. we reviewed clinical outcomes systematically with dabigatran as a direct oral anticoagulants (doac) for treatment of acute vte. we used ovide, pubmed, cochrane (central), embase, scopus, science direct, lilac(for article written not english) and also iranian database; magiran, isc, iran medex, iran doc, doaj up to may 2014 to identify randomized clinical trials of dabigatran compared with conventional treatment for vte. two investigators extracted data independently. number of 5107 patients including two trails were selected. the risk of recurrent vte was similar with the dabigatran and standard treatment (hazard ratio, 95% confidence interval 1.09 (0.76–1.57). dabigatran reduced the risk of minor bleeding in comparison with standard treatment; warfarin (0.62 (0.50–0.76). finally- in minor bleeding - the dabigatran seemed as effective as, and probably safer than standard treatment of acute vte. but in some aspects such as adherence to treatment, pregnant patient, impact on quality of life, new researches are needed to be clarified.